FASTCAP study on the management of hospitalized patients with community-acquired pneumonia: Pharmacoeconomic analysis of the prospective phase;Studio FASTCAP sulla gestione ospedaliera delle polmoniti acquisite in comunità: Valutazione farmacoeconomica della fase prospettica

Italian Journal of Medicine

Volumn 2, Issue 1, 2008, Pages 55-66

  Lazzaro, Carlo ^a,c   Iori, I ^b   Gussoni, G ^b  

^a Reggio Emilia Centro Studi FADOI ^*

^b Centro Studi FADOI   (Italy)

^c Studio di Economia Sanitaria   (Italy)

Author keywords

Antibiotic therapy; Community acquired pneumonia; Cost; Diagnostic therapeutic recommendations; Effectiveness

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CEFTRIAXONE; LEVOFLOXACIN; MACROLIDE;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; COMBINATION CHEMOTHERAPY; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; DRUG COST; DRUG EFFICACY; FEMALE; HOSPITAL PATIENT; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY;

EID: 45249115905     PISSN: 18779344     EISSN: None     Source Type: Journal    
DOI: 10.4081/itjm.2008.1.55     Document Type: Article

References (31)

1. Fine MJ, Smith MA, Carson CA, et al. Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. JAMA 1996;275(2):134-41.
2. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997;336(4):243-50.
3. Blasi F, Iori I, Bulfoni A, et al. Can CAP-guidelines adherence improve patient outcome in internal medicine departments? (Submitted to Eur Respir J, Jan 2008.)
4. Iori I, Gussoni G, Blasi F, et al. Linee guida e gestione ospedaliera delle polmoniti acquisite in comunità: l'esperienza italiana dello studio FASTCAP. Italian Journal Medicine 2008;2(1):5-18.
5. Blasi F, Bulfoni S, Concia E, et al. Gestione delle infezioni delle basse vie respiratorie in Medicina Interna. GIMI 2002;1(Suppl 2):1-69.
6. rd Ed. Oxford: Oxford University Press, 2005:39-43,55-101,103-36.
7. Grassi C, Casali L, Curti E, Tellarini M, Lazzaro C, Schito G; SMART Study Group. Studio Multicentrico con Moxifloxacina nel Trattamento delle Riacutizzazioni di Bronchite Cronica. Efficacy and safety of short course (5-day) moxifloxacin vs 7-day ceftriaxone in the treatment of acute exacerbations of chronic bronchitis (AECB). J Chemother 2002;14(6):597-608.
8. GioFil. VDANet. Banca Dati Sanitaria Farmaceutica (15 giugno 2007).
9. Trudu G, Iapichino G, Gattinoni L. Scheda di rilevamento delle ore di assistenza infermieristica in un reparto di terapia intensiva. Scenario 1987;3:14-6.
10. Pucci P, Congiu P, Cagliendo A, et al. Valutazione del potenziale di risparmio di costi diretti derivante dall'utilizzo delle cefalosporine parenterali unum in die in ambiente ospedaliero. Milano: IMS Health, 1992.
11. Lazzaro C. Analisi di minimizzazione dei costi del trattamento della leucemia cronica con fludarabina fosfato (Fludara®) ev e po: metodologia e risultati. Farmeconomia Percorsi Terapeutici 2004;5:265-72.
12. Ospedale Maggiore di Milano. Rapporta di Gestione 1999. Milano: Ospedale Maggiore di Milano, 2001.
13. Turolla A. La determinazione e il controllo dei costi nelle organizzazioni ospedaliere. Milano: Giuffrè, 1997:43-74.
14. Sistema Statistico Nazionale. Istituto Nazionale di Statistica. Compendio statistico italiano. www.istat.it/Anumital/Astatset/prez.htm (7 Iuglio 2007).
15. Siegel JE, Weinstein MC, Torrance GW. Reporting cost-effectiveness studies and results. In: Gold MR, Siegel JE, Russel LB, Weinstein MC (eds). Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996:276-303.
16. Briggs A, Schulper M, Claxton K. Decision modelling for health economic evaluation. Oxford: Oxford University Press, 2006:4-5.
17. Drummond MF, Becker DL, Hux M, et al. An economic evaluation of sequential iv/po moxifloxacin therapy compared to iv/po co-amoxiclav with or without clarithromycin in the treatment of community-acquired pneumonia. Chest 2003;124(2):526-35.
18. Ramirez JA. Switch therapy with beta-lactam/beta-lactamase inhibitors in patients with community-acquired pneumonia. Ann Pharmacother 1998;32(1):S22-6.
19. Viale P, Scudeller L, Petrosillo N, et al. Clinical stability in human immunodeficiency virus-infected patients with community-acquired pneumonia. Clin Infect Dis 2004;38(2):271-9.
20. Fine MJ, Pratt HM, Obrosky DS, et al. Relation between length of hospital stay and costs of care for patients with community-acquired pneumonia. Am J Med 2000;109(5):378-85.
21. Wasserfallen JB, Erard V, Cometta A, Calandra T, Lamy O. Cost-effectiveness of full-course oral levofloxacin in severe community-acquired pneumonia. Eur Respir J 2004;24(4):644-8.
22. Cavallo MC, Lazzaro C, Tabacchi M, et al. Il costo del reparte di terapia intensiva in Italia: risultati da un'indagine empirica su un campione di 12 centri. Minerva Anestesiol 2001;67:41-53.
23. Oosterheert JJ, Bonten MJ, Schneider MM, et al. Effectiveness of early switch from intravenous to oral antibiotics in severe community acquired pneumonia: multicentre randomised trial. BMJ 2006;333(7580):1193.
24. Ramirez JA, Vargas S, Ritter GW, et al. Early switch from intravenous to oral antibiotics and early hospital discharge: a prospective observational study of 200 consecutive patients with community-acquired pneumonia. Arch Intern Med 1999;159(20):2449-54.
25. Lee RW, Lindstrom ST. Early switch to oral antibiotics and early discharge guidelines in the management of community-acquired pneumonia. Respirology 2007;12(1):111-6.
26. Fernández-Sabé N, Carratalà J, Rosón B, et al. Community-acquired pneumonia in very elderly patients: causative organisms, clinical characteristics, and outcomes. Medicine 2003;82(3):159-69.
27. Baddour LM, Yu VL, Klugman KP, et al; International Pneumococcal Study Group. Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am J Respir Crit Care Med 2004;170(4):440-4.
28. Weiss K, Tillotson GS. The controversy of combination vs monotherapy in the treatment of hospitalized community-acquired pneumonia. Chest 2005;128(2):940-6.
29. Mandell LA, Wunderink RG, Anzueto A, et al; Infectious Diseases Society of America; American Thoracic Society. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44(Suppl 2):S27-72.
30. Mark DB, Hlatky MA, Califf RM, et al. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med 1995;332(21):1418-24.
31. Messori A, Santarlasci B, Trippoli S, Vaiani M. Controvalore economico del farmaco e beneficio clinico: stato dell'arte della metodologia e applicazione di un algoritmo farmacoeconomico. PharmacoEconomics Italian Research Articles 2003;5:53-67.